

# Is prophylactic HIPEC after colorectal cancer surgery the right strategy?




## Management of Peritoneal Surface Malignancy

**Irkutsk, Sibiria**

F.Quénet  
ICM Montpellier  
France

# Preoperative assessment of PC



**CT scan : Sensitivity: 60-79%**

**Pet-Scan : Se 57%**



Under-estimation of the extent of disease  
Sensitivity < 30% if < 0,5mm

PC diagnosed preoperatively in 55% of cases

# Results of Systematic Second-look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis

*D Elias, MD, PhD,\* C Honoré, MD,\* F Dumont, MD,\* M. Ducreux, MD, PhD,† V. Boige, MD, PhD,†  
D. Malka, MD, PhD,† P. Burtin, MD,† C. Dromain, MD,‡ and D. Goéré, MD\**

Ann Surg 2011;254:289–293

A macroscopic PC was found and treated in 23/41 patients, **(56%)**

Initial PC (n=25)	Ovarian Metastasis (n=8)	Perforation (n=8)
62%	60%	37%

➤ Mortality	2%
➤ Morbidity (grade III/IV)	10%.
➤ Mean hospital stay	21days




# Results of Systematic Second-look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis

*D Elias, MD, PhD,\* C Honoré, MD,\* F Dumont, MD,\* M. Ducreux, MD, PhD,† V. Boige, MD, PhD,†  
D. Malka, MD, PhD,† P. Burtin, MD,† C. Dromain, MD,‡ and D. Goéré, MD\**

*Annals of Surgery* • Volume 254, Number 2, August 2011

- Median OS was not reached
- 5-year OS rate : 90%
- 5-year RFS rate : 44%
- 7 out of the 41 patients (17%) relapsed in the peritoneum
  - 1 patient in the PC0 group (6%)
  - 6 in the PC + group (26%) (  $P = 0.006$ ).



Median follow up : 30 months

Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer?

Charles Honoré, Maximiliano Gelli, Julie Francoual, Léonor Benhaim, Dominique Elias & Diane Goéré



The search strategy identified 259 new articles to add to the 6522 articles initially analysed...

# Synchronous peritoneal metastases

(completely resected during the primary tumour surgery)

- Unexpected synchronous PM are discovered peroperatively in 4.8 –7.3% of patients with colorectal cancer scheduled for surgery.
- Recurrent PM rate is estimated between 54% and 71% at 1year with a high level of evidence

# Synchronous ovarian metastasis



- Unexpected synchronous ovarian metastases are synchronously found in **0.8–7.4%**
- But are associated with synchronous PM in **29–72%** of the cases
- the rate of recurrent PM in patients with isolated synchronous ovarian metastases is estimated between **62% and 71%** at 1year with a high level of evidence (2b).

# Perforated primary tumour



- The incidence of colorectal cancer presenting with a perforated primary tumour is ranging from 1.6% to 5.4%
- The incidence of recurrent PM after surgery for a perforated primary tumour is 27% at one year with a low level of evidence



# Primary tumour with serosa and/or adjacent organ invasion

---

- T4 is found in 13.7% of all colorectal cancer
- The incidence of recurrent PM after surgery for a pT4 tumour is 15.6% at 1 year and 36.7% at 3 years with a low level of evidence (3a).

# Mucinous histological subtype



- Mucinous adenocarcinoma and signet ring cell carcinoma (SRC) account, respectively, for **3–15% and for 0.1–2.4%**
- Recurrent PM in patients with MA or with a mucinous/SRC component is estimated between **11% and 36%** with a low level of evidence (3b).

# Positive peritoneal cytology

---

- The incidence of positive peritoneal cytology, without distinguishing tumour stages and detecting methods, ranges between 2.2% and 52%
- The incidence of recurrent PM after surgery for colorectal cancer with positive peritoneal cytology is estimated between 0% and 36% with a very poor level of evidence (3b–4).

# Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer

**J. Segelman\***, **O. Akre†**, **U. O. Gustafsson‡**, **M. Bottai§** and **A. Martling\***

\*Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, †Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ‡Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden and §Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

Received 6 September 2013; accepted 2 December 2013; Accepted Article online 10 January 2014

Risk of metachronous peritoneal carcinomatosis  
from colorectal cancer

☒ Colon cancer    ☐ Rectal cancer

	1 year 12.5%	2 years 23.7%	3 years 31.1%
Age	<input type="text" value="60"/>		
Primary site (colon)	<input checked="" type="checkbox"/> Left	<input type="checkbox"/> Right	<input type="checkbox"/> Transverse
pT stage	<input type="checkbox"/> T0-T2	<input type="checkbox"/> T3	<input checked="" type="checkbox"/> T4
pN stage	<input type="checkbox"/> N0	<input checked="" type="checkbox"/> N1	<input type="checkbox"/> N2
Radicality	<input checked="" type="checkbox"/> R0	<input type="checkbox"/> R1	<input type="checkbox"/> R2
Type of surgery	<input checked="" type="checkbox"/> Elective <input type="checkbox"/> Emergency		
Preoperative radiotherapy	<input type="checkbox"/> No <input type="checkbox"/> Yes		
Number of examined lymph nodes	<input checked="" type="checkbox"/> ≥12 <input type="checkbox"/> 0-11		
Adjuvant chemotherapy	<input type="checkbox"/> No <input checked="" type="checkbox"/> Yes		

**Figure 2** The web-calculator, equivalent to Tables 3 and 4, presents predicted probabilities of peritoneal recurrence after resection of Stage I–III colorectal cancer. <http://www.imm.ki.se/biostatistics/calculators/pcrisk/>.

# Patients at risk

## More than 40%

- Ovarian metastasis
- Resected localized PC
- Perforated tumors

## 8 to 30%

- T4 tumors
- Positive peritoneal cytology
- Obstructive or bleeding tumors
- Mucinous tumors

# Standard risk patients



- No evidence of an increased incidence of recurrent PM was found in patient with
  - Bleeding primary tumours
  - occlusive primary tumours
  - invaded lymph node
  - after laparoscopic resection
- The running risk of PM is evaluated in this category between 3.4% and 6.3%

*Clinical Study*

**Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results**

A. A. K. Tentes,<sup>1</sup> I. D. Spiliotis,<sup>2</sup> O. S. Korakianitis,<sup>3</sup> A. Vaxevanidou,<sup>4</sup> and D. Kyziridis<sup>1</sup>





- HIPEC in 40 patients with a T3/T4 tumour without synchronous PM
- Recurrent PM rate of 0% after 17 months of median follow-up.

# Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases

P. Sammartino • S. Sibio • D. Biacchi • M. Cardi •  
P. Mingazzini • M. S. Rosati • T. Cornali • B. Sollazzo •  
J. Maherfouad Atta • A. Di Giorgio

- 25 patients with a mucinous T3/T4 tumour without synchronous PM who underwent HIPEC were compared with 50 patients treated with standard surgical resection
- The peritoneal recurrence rate was significantly lower in the group that received HIPEC (4% vs. 22%)
- with similar overall recurrence rates (28% vs. 32%)






# ProphyloCHIP TRIAL



Multicentric Phase III Trial Comparing  
Simple Follow-up to Exploratory Laparotomy Plus "in Principle" HIPEC  
in Colorectal Patients Initially Treated With Surgery and Adjuvant  
Chemotherapy at High Risk of Developing Colorectal Peritoneal  
Carcinomatosis


PI: D.Elias

# ProphyloCHIP Trial Design



# The Dutch Study: COLOPEC

PI: IH de Hingh



56/173 patients included

# Conclusions

---

- Situations at higher risk of recurrent PM are
  - synchronous PM
  - synchronous isolated ovarian metastases
  - perforated primary tumour
  - tumour with serosa invasion
  - mucinous histological subtype
- Further studies are now required to evaluate effective means to prevent PC occurrence